Skip to content

Characterization of AmnioExcel Plus in Two Treatment Paradigms

Characterization of AmnioExcel Plus in Two Treatment Paradigms

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04233580
Enrollment
40
Registered
2020-01-18
Start date
2020-07-09
Completion date
2021-04-06
Last updated
2023-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcer

Brief summary

The Investigators plan to evaluate healing in two cohorts of patients with diabetic foot wounds (n=20) that receive optimal treatment including serial wound debridement and off-loading with a boot or postop shoe and AmnioEXCEL+. In one cohort, AmnioEXCEL+ will be applied weekly at study visits and in the second cohort, AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC). In addition, the Investigators will collect data on other potential confounding factors that could affect healing such as antibiotic, anti-fungal and anti-infective medications, tobacco, comorbidities, diabetes control, infection, perfusion, and activity. Wound healing, including wound size and adverse events will be evaluated.

Detailed description

Study Procedures: Collection of Demographic data, medical/social history Collection of medications1 Ankle Brachial Index2 Wound debridement3 (standard of care procedure) Imaging with eKare4 Hyperspectral Imaging Application of study product 1. Only collect antibiotics, anti-fungal and anti-infective medications. 2. ABI (with toe pressure) can be done at screening or baseline. 3. Once wound is healed, wound debridement will not be done at weekly visits. 4. Once wound is healed, eKare will not be done at weekly visits. 5. EOS will occur on the date the subject is healed. \*Screening and Visit 1 may be done on the same day. Screening and Enrollment\*: * Review and sign the Informed Consent and HIPAA Authorization * Review the inclusion and exclusion criteria If the subject qualifies for the study, they will participate in the following procedures (weekly visits, +/-4 days): Visit 1\*: * Demographics (such as age, gender, race or ethnicity) * Past Medical History, Social History, Medications documented. * Labs documented as SOC within 6mo of initial visit * ABI with toe pressures2 * Wound debridement * eKare wound measurement * Hyperspectral Imaging * Randomization * Application of AmnioEXCEL+ * Source documentation * Stipend disbursement Visits 2 through 6: * Wound debridement3 * eKare wound measurement4 * Hyperspectral imaging * Application of AmnioEXCEL+ per cohort assignment * Source documentation * Stipend disbursement Visit 7: * Medications documented * Wound debridement3 * eKare wound measurement4 * Hyperspectral imaging * Application of AmnioEXCEL+ per cohort assignment * Source documentation * Stipend disbursement Visits 8-11: * Wound debridement3 * eKare wound measurement4 * Hyperspectral Imaging * Application of AmnioEXCEL+ per cohort assignment * Source documentation * Stipend disbursement Visit 12: * Wound debridement3 * eKare wound measurement4 * Source documentation * Stipend disbursement End of Study (EOS) Visit 5: * Medications documented * Wound debridement3 * eKare wound measurement4 * Source documentation * Subject exit from study

Interventions

DEVICEAmnio Excel + weekly

Amnio Excel + weekly

DEVICEAmnio Excel + max every 2 weeks

Amnio Excel + max every 2 weeks

Sponsors

Integra LifeSciences Corporation
CollaboratorINDUSTRY
University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Criteria for Inclusion of Subjects: * 21-90 years of age * Able to provide informed consent * Chronic foot ulceration below the ankle - persistent for \>30 days but \<6 months Criteria for Exclusion of Subjects: * \<21 or \>90 years of age * Unable to provide informed consent * History of poor compliance in the opinion of the investigator * Gangrene * Untreated osteomyelitis * Widespread malignancy * Active alcohol or substance abuse such as cocaine, heroin, or methamphetamines that in the opinion of the investigator will impact the subject's participation in the study * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Who Healed12 weeksNumber of participants whose wounds healed during the study timeframe. Reported as dichotomous yes/no.

Secondary

MeasureTime frameDescription
Wound VolumeBaselineWound volume measured by camera which performs a 3D measurement and calculates the volume at baseline
Wound AreaBaselineWound measured by camera which performs a 3D measurement and calculates the area at baseline
Tissue Oxygenation (StO2) of the Dorsal FootBaselineTissue oxygenation measured by hyperspectral imaging camera at baseline

Countries

United States

Participant flow

Participants by arm

ArmCount
Weekly AmnioEXCEL+ Group
AmnioEXCEL+ will be applied weekly at study visits Amnio Excel + weekly: Amnio Excel + weekly
20
PRN AmnioEXCEL+ Group
AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC) Amnio Excel + max every 2 weeks: Amnio Excel + max every 2 weeks
20
Total40

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event33
Overall StudyWithdrawal by Subject21

Baseline characteristics

CharacteristicWeekly AmnioEXCEL+ GroupPRN AmnioEXCEL+ GroupTotal
Age, Continuous58.9 years
STANDARD_DEVIATION 15.3
57.6 years
STANDARD_DEVIATION 9.8
58.43 years
STANDARD_DEVIATION 12.7
Body mass index32.2 kg/m^2
STANDARD_DEVIATION 7.8
32.3 kg/m^2
STANDARD_DEVIATION 5
32.3 kg/m^2
STANDARD_DEVIATION 6.6
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants4 Participants8 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
16 Participants16 Participants32 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Neuropathy18 Participants18 Participants36 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
4 Participants7 Participants11 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
15 Participants13 Participants28 Participants
Region of Enrollment
United States
20 participants20 participants40 participants
Sex: Female, Male
Female
6 Participants5 Participants11 Participants
Sex: Female, Male
Male
14 Participants15 Participants29 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 200 / 20
other
Total, other adverse events
9 / 207 / 20
serious
Total, serious adverse events
6 / 205 / 20

Outcome results

Primary

Number of Participants Who Healed

Number of participants whose wounds healed during the study timeframe. Reported as dichotomous yes/no.

Time frame: 12 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Weekly AmnioEXCEL+ GroupNumber of Participants Who Healed6 Participants
PRN AmnioEXCEL+ GroupNumber of Participants Who Healed10 Participants
Secondary

Tissue Oxygenation (StO2) of the Dorsal Foot

Tissue oxygenation measured by hyperspectral imaging camera at baseline

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Weekly AmnioEXCEL+ GroupTissue Oxygenation (StO2) of the Dorsal Foot65.89 percentage of oxygen saturationStandard Deviation 15.41
PRN AmnioEXCEL+ GroupTissue Oxygenation (StO2) of the Dorsal Foot65.70 percentage of oxygen saturationStandard Deviation 9.31
Secondary

Wound Area

Wound measured by camera which performs a 3D measurement and calculates the area at baseline

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Weekly AmnioEXCEL+ GroupWound Area3.98 square centimetersStandard Deviation 4.87
PRN AmnioEXCEL+ GroupWound Area3.15 square centimetersStandard Deviation 4.05
Secondary

Wound Volume

Wound volume measured by camera which performs a 3D measurement and calculates the volume at baseline

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Weekly AmnioEXCEL+ GroupWound Volume1.2 cubic centimetersStandard Deviation 3.27
PRN AmnioEXCEL+ GroupWound Volume0.53 cubic centimetersStandard Deviation 1.44

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026